ONCO3R B2 Patent - Heterocyclic Compounds and Pharmaceutical Compositions for Disease Treatment
Summary
The USPTO granted US Patent 12,606,554 B2 to ONCO3R Therapeutics BV on April 21, 2026. The patent covers heterocyclic compounds according to Formula I and pharmaceutical compositions for treating inflammatory, autoinflammatory, autoimmune, proliferative, fibrotic diseases, transplant rejection, and diseases involving impairment of cartilage or bone turnover, as well as conditions associated with hypersecretion of IL-6, TNFα, interferons, IL-12 and/or IL-23. The patent contains 19 claims and was filed on May 25, 2020.
What changed
USPTO issued Patent 12,606,554 B2 to ONCO3R Therapeutics BV, covering compounds and pharmaceutical compositions for treatment of multiple disease categories including inflammatory, autoimmune, proliferative, and fibrotic diseases. The patent was filed under application 17614814 on May 25, 2020, and granted April 21, 2026, with 19 claims.
Third parties should note this patent grants exclusive rights to ONCO3R Therapeutics BV for the specified heterocyclic compounds and their pharmaceutical applications. Companies developing competing therapeutics in these therapeutic areas should conduct freedom-to-operate analyses to assess potential infringement risks.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Compounds and pharmaceutical compositions thereof for the treatment of diseases
Grant US12606554B2 Kind: B2 Apr 21, 2026
Assignee
ONCO3R Therapeutics BV
Inventors
Taoues Temal-Laïb
Abstract
The present invention discloses compounds according to Formula I:
wherein R1, R2a, W, X1, X2, Y and Z are as defined herein.
The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformation, diseases involving impairment of bone turnover, diseases associated with hypersecretion of IL-6, diseases associated with hypersecretion of TNFα, interferons, IL-12 and/or IL-23, respiratory diseases, endocrine and/or metabolic diseases, cardiovascular diseases, dermatological diseases, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.
CPC Classifications
C07D 471/04 C07D 487/04 A61P 1/04 A61P 11/00 A61P 9/02
Filing Date
2020-05-25
Application No.
17614814
Claims
19
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.